Last $23.20 USD
Change Today +0.09 / 0.39%
Volume 362.8K
QGEN On Other Exchanges
Symbol
Exchange
Xetra
NASDAQ GS
As of 5:10 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

qiagen n.v. (QGEN) Snapshot

Open
$23.03
Previous Close
$23.11
Day High
$23.33
Day Low
$23.01
52 Week High
07/18/14 - $25.32
52 Week Low
04/15/14 - $19.46
Market Cap
5.4B
Average Volume 10 Days
814.7K
EPS TTM
$0.68
Shares Outstanding
232.3M
EX-Date
--
P/E TM
34.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for QIAGEN N.V. (QGEN)

qiagen n.v. (QGEN) Related Businessweek News

No Related Businessweek News Found

qiagen n.v. (QGEN) Details

QIAGEN N.V. provides sample and assay technologies worldwide. It offers approximately consumable products, such as sample and assay kits, and automated instrumentation systems that empower customers to transform raw biological samples into molecular information. The company’s consumable products are used for plasmid deoxyribonucleic acid (DNA) purification, and ribonucleic acid purification and stabilization; genomic and viral nucleic acid purification; nucleic acid transfection; polymerase chain reaction (PCR) amplification; reverse transcription; DNA cleanup after PCR and sequencing; and DNA cloning and protein purification. The company sells the digene HC2 HPV Test for high-risk strains of the human papillomavirus. It also offers co-development services for companion diagnostics, technology licensing and patent sales services, and custom services, including whole genome amplification, DNA sequencing, and non-cGMP DNA production on a contract basis. In addition, the company provides instrumentation systems that automate the use of sample and assay technologies into solutions for a range of laboratory needs enabling customers to perform nucleic acid sample preparation, assay setup, and target detection, as well as workflow solutions. Its automated systems include QIAsymphony, a modular system; Rotor-Gene Q, a rotary real-time PCR cycler system; PyroMark, a high-resolution detection platform; QIAcube, a sample processing instrument; QIAxcel for nucleic acid separation; and ESE-Quant tube scanners. The company serves molecular diagnostics laboratories; applied testing customers; pharmaceutical research and development groups, and academic researchers. It has a collaboration agreement with AstraZeneca PLC to co-develop and commercialize liquid biopsy-based companion diagnostic; and Astellas Pharma Inc. to develop and commercialize companion diagnostics for use in cancer and other diseases. QIAGEN N.V. was founded in 1986 and is headquartered in Venlo, the Netherlands.

4,200 Employees
Last Reported Date: 10/31/14
Founded in 1986

qiagen n.v. (QGEN) Top Compensated Officers

Chairman of Management Board, Chief Executive...
Total Annual Compensation: $1.5M
Chief Financial Officer, Managing Director an...
Total Annual Compensation: $639.5K
Compensation as of Fiscal Year 2013.

qiagen n.v. (QGEN) Key Developments

Qiagen N.V. to Distribute Altona Diagnostic's Realstar Ebolavirus RT-PCR Kit 1.0

Qiagen N.V. announced it will offer global distribution of the altona Diagnostics RealStar Ebolavirus RT-PCR Kit 1.0 after the U.S. Food and Drug Administration amended, on November 26, 2014 to permit authorized distribution and use in US and certain non-US laboratories, an Emergency Use Authorization originally issued on November 10, 2014, for this kit. The diagnostic kit, developed and manufactured by altona Diagnostics GmbH, is a reverse transcription polymerase chain reaction test intended for the qualitative detection of RNA from all known strains of Ebolaviruses, including the Zaire strain driving the current Ebola epidemic in West Africa. QIAGEN has agreed to distribute the RealStar Ebolavirus RT-PCR Kit 1.0 in addition to altona's already CE-IVD marked test, the RealStar Filovirus RT-PCR Kit, which is for both Ebola and Marburg viruses and does not fall under the EUA. The RealStar Ebolavirus kit is authorized for emergency use on specified instruments in plasma from individuals with signs and symptoms of Ebolavirus infection in conjunction with clinical and epidemiological risk factors. As authorized by the FDA under EUA, the test has not been FDA cleared or approved. It has been authorized by the FDA under an Emergency Use Authorization for use by CLIA High Complexity Laboratories and similarly qualified non-U.S. laboratories and only for the detection - not differentiation - of RNA from Ebolaviruses and not for any other viruses or pathogens. Furthermore, this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostics for detection of Ebola Zaire virus under section 564 of the Act, 21 U.S.C. -- 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. QIAGEN's agreement with altona Diagnostics to distribute the FDA-authorized RealStar Ebolavirus RT-PCR Kit 1.0 expands an existing collaboration between the two companies which was signed in the third quarter of 2014. Under the earlier agreement, QIAGEN is also distributing the RealStar Filovirus RT-PCR Kit, which does not fall under the EUA, outside the United States. This highly sensitive test for Filoviruses that is CE-IVD marked for use on QIAGEN instruments and with QIAGEN sample technologies outside the United States is also compatible with other widely used detection platforms present in many laboratories, helping to avoid the need for new equipment and additional trainings. Other QIAGEN molecular testing technologies not covered by the EUA include components such as the EZ1 Virus Mini Kit v2.0, RNeasy and QIAamp Viral RNA Mini extraction kits as well as flexible automation platforms such as the QIAsymphony family, QIAcube and EZ1 Advanced instruments, which are being used by many laboratories around the world for Ebola research and diagnosis. Finally, QIAGEN's bioinformatics tools such as the CLC Genomics Workbench and Ingenuity Pathway Analysis have contributed to generating valuable insights into research on genetic factors driving individual response to Ebola infections.

Qiagen Mulls Acquisitions

Qiagen NV (NasdaqGS:QGEN) is looking for acquisitions. John Gilardi, Vice President of Corporate Communications at Qiagen NV said, "You should be looking for us to be doing acquisitions in the area of NGS, bioinformatics, areas where we can put content on our systems and drive the dissemination of molecular testing."

QIAGEN N.V. Enters into Master Collaboration Agreement with Novartis AG

QIAGEN N.V. announced it has entered into a master collaboration agreement with Novartis AG to enable the development and commercialization of companion diagnostics to be paired with existing Novartis pharmaceutical products as well as compounds in its development pipeline. The non-exclusive agreement with Novartis creates a framework for collaborations that would include developing QIAGEN companion diagnostics to guide treatment decisions for Novartis pharmaceutical products. The scope of the collaboration can cover all QIAGEN platforms, indications or biomarkers. The collaboration with Novartis is the ninth master framework agreement reached by QIAGEN for the development of companion diagnostics, underscoring its position as the preferred partner to pharma companies. QIAGEN is pursuing more than 20 collaborative projects with Pharma and biotech companies to develop, validate and market companion diagnostics designed to guide the treatment of cancers and other diseases. Around the world, QIAGEN already markets companion diagnostics based on molecular biomarkers, and the company has a growing portfolio of novel targets in development. The companion diagnostic programs span a range of platforms for molecular testing. A number of the diagnostics are real-time PCR assays for analysis on QIAGEN's Rotor-Gene Q, a component of the QIAsymphony family of automated instruments.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QGEN:US $23.20 USD +0.09

QGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioMerieux €86.13 EUR -0.07
Cepheid $53.39 USD +0.51
Hologic Inc $26.89 USD +0.10
Myriad Genetics Inc $36.50 USD +0.28
PerkinElmer Inc $43.99 USD -0.06
View Industry Companies
 

Industry Analysis

QGEN

Industry Average

Valuation QGEN Industry Range
Price/Earnings 43.7x
Price/Sales 4.1x
Price/Book 2.0x
Price/Cash Flow 43.5x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QIAGEN N.V., please visit www.qiagen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.